Faculty, Staff and Student Publications

Publication Date

3-1-2025

Journal

Nature

Abstract

Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens1-6. However, whether such responses can target cancer driver mutations, lead to immune recognition of a patient's tumour and result in clinical activity are largely unknown. These questions are of particular interest for patients who have tumours with a low mutational burden. Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine. At a median follow-up of 40.2 months after surgery, none of the 9 participants enrolled in the study had a recurrence of RCC. No dose-limiting toxicities were observed. All patients generated T cell immune responses against the PCV antigens, including to RCC driver mutations in VHL, PBRM1, BAP1, KDM5C and PIK3CA. Following vaccination, there was a durable expansion of peripheral T cell clones. Moreover, T cell reactivity against autologous tumours was detected in seven out of nine patients. Our results demonstrate that neoantigen-targeting PCVs in high-risk RCC are highly immunogenic, capable of targeting key driver mutations and can induce antitumour immunity. These observations, in conjunction with the absence of recurrence in all nine vaccinated patients, highlights the promise of PCVs as effective adjuvant therapy in RCC.

Keywords

Humans, Carcinoma, Renal Cell, Kidney Neoplasms, Cancer Vaccines, Antigens, Neoplasm, Male, Female, Middle Aged, Aged, Mutation, T-Lymphocytes, Ipilimumab, Class I Phosphatidylinositol 3-Kinases, Precision Medicine, Nuclear Proteins, Adult, Von Hippel-Lindau Tumor Suppressor Protein, Transcription Factors, DNA-Binding Proteins, Tumor Suppressor Proteins, Ubiquitin Thiolesterase

DOI

10.1038/s41586-024-08507-5

PMID

39910301

PMCID

PMC11903305

PubMedCentral® Posted Date

2-5-2025

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.